We then analyzed the impact of combined inhibition of CHK1 and RAD51 (by prexasertib+B02) and CHK1 and MRE11 (by prexasertib+mirin) on DNA replication and DNA damage in CRC-SCs. Here, RAD51 is linked to colorectal carcinoma.